Pharmacovigilance Services in Italy

The pharmaceutical landscape in Italy has undergone a significant structural transformation as of 2026. This shift is driven by the AIFA (Agenzia Italiana del Farmaco) governance reform, the integration of the EU Health Technology Assessment (HTA) Regulation, and the exponential adoption of Artificial Intelligence (AI) in safety monitoring (AI in Regulatory Affairs Market Report, 2026; Remap Consulting, 2026).

Pharmacovigilance Services in Italy ensure drug safety, monitoring adverse effects post-market, while Regulatory Services in Italy govern the authorization and compliance of therapeutic goods, upholding healthcare standards.

1. Regulatory Framework and AIFA Reform

As of 2026, the traditional distinction between technical and economic evaluation in Italy has been streamlined. The previous CTS (Technical Scientific Committee) and CPR (Pricing and Reimbursement Committee) have been replaced by a single entity: the Commissione Scientifica ed Economica del farmaco (CSE) (Remap Consulting, 2026).

EU HTA Alignment: Effective April 1, 2026, AIFA’s updated HTA guidelines align strictly with EU Regulation 2021/2282. This means that Joint Clinical Assessments (JCA) conducted at the EU level are now the foundation for Italian submissions, reducing duplication of clinical evidence (Remap Consulting, 2026; PMC, 2026).

Localized Value Narratives: While clinical data is centralized, manufacturers must now focus more intensely on the "Italian value story," incorporating local epidemiology, treatment pathways, and economic impact to secure pricing and reimbursement (Remap Consulting, 2026).

2. Advanced Pharmacovigilance (PV) and AI

Pharmacovigilance in Italy has moved from reactive monitoring to proactive, AI-driven surveillance. The market for AI in regulatory affairs is projected to reach $2.11 billion in 2026, with a CAGR of 23% (AI in Regulatory Affairs Market Report, 2026).

AI-Driven Safety Monitoring

Automated Case Processing: AI algorithms now automate the intake of Individual Case Safety Reports (ICSRs), extracting data from unstructured text and coding medical terms using standardized dictionaries like MedDRA (Baupharma, 2026).

Signal Detection: Predictive modeling and natural language processing (NLP) are used to identify safety signals much earlier than traditional manual reviews by scanning global literature and social media (Baupharma, 2026).

Regulatory Inspection Readiness

With the release of joint EMA–FDA guiding principles in early 2026, AI systems used in PV must be "inspection-ready." In Italy, this requires:

Traceability: Every AI-assisted decision must be reconstructible for auditors (Clinevo, 2026).

Human-in-the-loop: Regulatory authorities require defined "confidence thresholds" where the AI must escalate a case to a human professional (Clinevo, 2026).

3. Specialized Regulatory Updates

In early 2026, AIFA published revised guidance for Over-the-Counter (OTC) and Non-Prescription (SOP) medicines, replacing decades-old circulars (Regask, 2026; Regulatory Pharma Net, 2026).

Classification Criteria: To be classified as OTC, a drug must demonstrate at least five years of safe use in Europe or the UK and be intended for mild, self-managed conditions (Regulatory Pharma Net, 2026).

Digital Health: Italian authorities have aligned with the EU AI Act, requiring clinical validation for any AI/ML algorithms used in software as a medical device (SaMD) to ensure reliable outcomes across diverse populations (ICLG.com, 2026).

Summary Table: Key 2026 Italian Regulatory Milestones